logo
FDA Issues Highest Risk Warning for Nationwide Chocolate Recall

FDA Issues Highest Risk Warning for Nationwide Chocolate Recall

Newsweek10-07-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A nationwide recall of chocolate products has been issued the highest risk warning by the U.S. Food and Drug Administration (FDA).
Weaver Nut Company, Inc., based in Pennsylvania, announced a voluntary recall for specific lots of its semi-sweet chocolate nonpareils on June 17 due to the possible undeclared presence of milk, a major food allergen.
The FDA subsequently issued a Class 1 risk classification for the recall on July 8.
Newsweek contacted Weaver Nut Company, Inc. for comment by email outside of regular working hours.
Stock image: Some chocolate treats are seen on a white background.
Stock image: Some chocolate treats are seen on a white background.
Press Association/AP Images
Why It Matters
A Class I risk classification represents "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," according to the FDA.
The recall was initiated due to the undeclared presence of milk, one of the nine major food allergens as defined in law. The others are eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and wheat.
The FDA warned that people with an allergy or severe sensitivity to milk "run the risk of serious or life-threatening allergic reaction if they consume the impacted products."
Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems.
What To Know
The products impacted by the recall include:
Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)—849 cases—item number: 47518—lot numbers: 204206, 204207, 204208, 204209, 204212, 224225
Nonpareils, Semi-Sweet Chocolate (White Seeds)—1760 cases—item number: D2645—lot numbers: 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1
The products were distributed to customers throughout the U.S., and sold at various retail and grocery stores.
The issue was identified after a wholesale customer submitted a complaint regarding discrepancies with product specifications, the FDA said in its release.
Subsequent laboratory testing confirmed the presence of milk in the chocolates, which were labeled free from milk, it added.
As of June 17, no illnesses had been reported in connection with the consumption of the products.
What People Are Saying
Weaver Nut Company, Inc. said in the FDA's recall notice: "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products."
The FDA said on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, told Newsweek previously: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
The recall is listed as ongoing, according to the FDA.
Consumers who purchased the products and have a milk allergy are urged to discard them immediately, or return them to their place of purchase for a full refund.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

The Hill

timean hour ago

  • The Hill

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Trump Brushes Off Major Success From First Term: 'Long Time Ago'
Trump Brushes Off Major Success From First Term: 'Long Time Ago'

Newsweek

timean hour ago

  • Newsweek

Trump Brushes Off Major Success From First Term: 'Long Time Ago'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump on Wednesday brushed off what is widely considered to be among the biggest uncontested successes of his first term while reacting to Health and Human Services Secretary Robert F. Kennedy Jr.'s move to pull $500 million in funding for next-generation mRNA-based vaccines to tackle viruses like Covid, H5N1 and the flu. "You were the driving force behind Operation Warp Speed, these mRNA vaccines that are the gold standard," a reporter asked Trump during a White House event on Wednesday. Operation Warp Speed was a 2020 public-private partnership, initiated by the first Trump administration, aimed at accelerating the development and distribution of a COVID-19 vaccine. At the time, it was almost universally accepted that an effective vaccine for the coronavirus was at least 18 months to two years away. Trump's operation did it in less than a year. "Now, your health secretary is pulling back all the funding for research, he's saying that the risks outweigh the benefits, which puts him at odds with the entire medical community, and with you," the reporter continued. "What's going on?" "Research on what?" Trump asked. "Into mRNA vaccines," she clarified. "Well, we're going to look at that," the president replied. "We're talking about it and they're doing a very good job, and you know, that is a pass." Trump went on to briefly acknowledge the success of Operation Warp Speed before dismissing it. "Operation Warp Speed was, whether you're a Republican or Democrat, considered one of the most incredible things ever done in this country," the president said. "The efficiency, the way it was done, the distribution, everything about it has been amazing." Then he added: "But, you know, that was now a long time ago. And we're onto other things, but we are speaking about it. We have meetings about it ... we're looking for other answers to other problems, to other sicknesses and diseases and I think we're doing really well." This is a breaking news story. Updates to follow.

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

Boston Globe

time2 hours ago

  • Boston Globe

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Marlborough-based Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. Advertisement In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. Advertisement As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store